Kargbo Robert B
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
ACS Med Chem Lett. 2024 Nov 11;15(12):2080-2082. doi: 10.1021/acsmedchemlett.4c00521. eCollection 2024 Dec 12.
Psychedelic compounds, particularly psilocybin and psilocin, have shown significant therapeutic potential in treating neurological and psychiatric disorders. However, their bioavailability, rapid metabolism, and stability challenges have limited their clinical use. This Patent Highlight reviews recent innovations in psychedelic drug delivery systems and the development of psilocin analogs aimed at improving their pharmacokinetic and pharmacodynamic profiles. Three patents-focused on controlled-release delivery systems, ester analogs, and acetal/ketal derivatives-present novel approaches to enhancing the stability, bioavailability, and efficacy of psilocin and related compounds. These advancements promise more effective treatments for conditions such as depression, chronic pain, and neurodegenerative diseases.
迷幻化合物，尤其是裸盖菇素和脱磷酸裸盖菇素，在治疗神经和精神疾病方面已显示出显著的治疗潜力。然而，它们的生物利用度、快速代谢和稳定性挑战限制了它们的临床应用。本专利亮点回顾了迷幻药物递送系统的最新创新以及旨在改善其药代动力学和药效学特征的脱磷酸裸盖菇素类似物的开发。三项专利——专注于控释递送系统、酯类似物和缩醛/缩酮衍生物——提出了增强脱磷酸裸盖菇素及相关化合物稳定性、生物利用度和功效的新方法。这些进展有望为抑郁症、慢性疼痛和神经退行性疾病等病症带来更有效的治疗方法。
